Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $14.57 Consensus Target Price from Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) has earned a consensus recommendation of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $14.57.

Several research firms have recently weighed in on VERV. Jefferies Financial Group cut Verve Therapeutics from a "buy" rating to a "hold" rating and cut their price objective for the company from $28.00 to $11.00 in a report on Wednesday, June 18th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Wall Street Zen upgraded Verve Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright lowered Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 price target on the stock. in a report on Wednesday, June 18th.

Hedge Funds Weigh In On Verve Therapeutics

Large investors have recently modified their holdings of the business. IFP Advisors Inc raised its holdings in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after acquiring an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics during the 4th quarter worth approximately $50,000. KFG Wealth Management LLC bought a new stake in shares of Verve Therapeutics during the 1st quarter worth approximately $46,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Verve Therapeutics in the 1st quarter valued at approximately $47,000. Finally, E Fund Management Co. Ltd. bought a new position in shares of Verve Therapeutics in the first quarter valued at $48,000. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Verve Therapeutics Stock Performance

NASDAQ:VERV traded up $0.02 during trading hours on Thursday, hitting $11.23. The stock had a trading volume of 1,140,860 shares, compared to its average volume of 2,440,104. The business's 50 day moving average is $6.52 and its 200-day moving average is $6.20. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -5.32 and a beta of 2.23. Verve Therapeutics has a one year low of $2.86 and a one year high of $11.41.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.36. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. On average, sell-side analysts anticipate that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.